AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39565703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandala coloring for a minimum of 30 minutes during and after chemotherapy treatment.
Number of subjects: 38
Study 39565703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mandala coloring).
Number of subjects: 38
Study 39565757 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 150
Study 39565757 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 39565905 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalus bioprosthesis
Number of subjects: 1132
Study 39565908 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1-2 treatment-related irAEs
Number of subjects: 684
Study 39565908 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3-4 treatment-related irAEs
Number of subjects: 684
Study 39565908 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1-2 dermatologic toxicity
Number of subjects: 684
Study 39565908 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1-2 fatigue, gastrointestinal, metabolic, hepatic, endocrine, and thyroid toxicities
Number of subjects: 684
Study 39565980 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization (adjunct to standard treatment)
Number of subjects: 310
Study 39565980 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 310
Study 39565990 — intervention group
Group type: EXPERIMENTAL
Intervention: GA2
Number of subjects: 20
Study 39565990 — intervention group
Group type: COMPARATOR
Intervention: GA1
Number of subjects: 20
Study 39565990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 39565989 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization with liquid embolic material
Number of subjects: 722
Study 39565989 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 722
Study 39565987 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based genetic carrier screening
Number of subjects: 10038
Study 39565988 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization plus surgery
Number of subjects: 400
Study 39565988 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 400
Study 39566036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration (total sleep time; TST)
Number of subjects: 48
Study 39566036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep timing (sleep onset and offset time)
Number of subjects: 48
Study 39566036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality (wake after sleep onset; WASO)
Number of subjects: 48
Study 39566048 — intervention group
Group type: EXPERIMENTAL
Intervention: YACHT program
Number of subjects: 42
Study 39566051 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 0
Study 39566051 — intervention group
Group type: COMPARATOR
Intervention: Sham-Control
Number of subjects: 0
Study 39566053 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based testing with direct in-home assessments
Number of subjects: 6000
Study 39566053 — intervention group
Group type: COMPARATOR
Intervention: Facility-based testing with subsequent referral
Number of subjects: 6000
Study 39566056 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39566128 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 62
Study 39566128 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment
Number of subjects: 62
Study 39566128 — intervention group
Group type: COMPARATOR
Intervention: Promestriene treatment (Control)
Number of subjects: 62
Study 39566293 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomy-Based Fitting (ABF)
Number of subjects: 20
Study 39566293 — intervention group
Group type: COMPARATOR
Intervention: Default Fitting (DF)
Number of subjects: 20
Study 39566404 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxinshi
Number of subjects: 681
Study 39566404 — intervention group
Group type: COMPARATOR
Intervention: Trimetazidine
Number of subjects: 681
Study 39566464 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab with chemotherapy
Number of subjects: 0
Study 39566464 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39566467 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous P63 transplantation
Number of subjects: 0
Study 39566600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD) - 75 g carbohydrates for 8 weeks
Number of subjects: 55
Study 39566600 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LED) - 180 g carbohydrates for 8 weeks
Number of subjects: 55
Study 39566722 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPP intervention (five-session, phone-delivered peer support)
Number of subjects: 90
Study 39566722 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPP intervention
Number of subjects: 90
Study 39566722 — intervention group
Group type: COMPARATOR
Intervention: Usual transplant care (control)
Number of subjects: 90
Study 39566872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 203
Study 39566872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 39566948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care plus usual medical care
Number of subjects: 750
Study 39566948 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care alone
Number of subjects: 750
Study 39566954 — intervention group
Group type: EXPERIMENTAL
Intervention: MdF's comprehensive intervention programme
Number of subjects: 360
Study 39566954 — intervention group
Group type: COMPARATOR
Intervention: Usual care in sociomedical structures
Number of subjects: 360
Study 39566994 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of care to adult healthcare
Number of subjects: 440
Study 39566994 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative care experiences after transfer of care
Number of subjects: 440
Study 39567210 — intervention group
Group type: EXPERIMENTAL
Intervention: IO-108 monotherapy
Number of subjects: 25
Study 39567210 — intervention group
Group type: EXPERIMENTAL
Intervention: IO-108 + pembrolizumab
Number of subjects: 25
Study 39567210 — intervention group
Group type: EXPERIMENTAL
Intervention: IO-108 monotherapy and combination therapy
Number of subjects: 25
Study 39567211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa monotherapy (6 µg/kg/day)
Number of subjects: 243
Study 39567211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa with pembrolizumab
Number of subjects: 243
Study 39567211 — intervention group
Group type: COMPARATOR
Intervention: Nemvaleukin alfa (dose-escalation)
Number of subjects: 243
Study 39567374 — intervention group
Group type: EXPERIMENTAL
Intervention: GET-WEL Program (Group-based Telehealth behavioral Weight Loss)
Number of subjects: 24
Study 39567430 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous consolidation (cementoplasty, screw fixation, or both)
Number of subjects: 138
Study 39567430 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous consolidation
Number of subjects: 138
Study 39567910 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk-based formula (GMF)
Number of subjects: 56
Study 39567910 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-based formula (CMF)
Number of subjects: 56
Study 39567939 — intervention group
Group type: EXPERIMENTAL
Intervention: Family members' experiences and roles during rehabilitation
Number of subjects: 20
Study 39567939 — intervention group
Group type: EXPERIMENTAL
Intervention: Typologies of family members' roles
Number of subjects: 20
Study 39567939 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of involvement in rehabilitation process
Number of subjects: 20
Study 39567939 — intervention group
Group type: EXPERIMENTAL
Intervention: Health considerations by healthcare professionals
Number of subjects: 20
Study 39567939 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of family members' perceptions on well-being
Number of subjects: 20
Study 39567961 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral brief-pulse ECT
Number of subjects: 36
Study 39567961 — intervention group
Group type: COMPARATOR
Intervention: Untreated healthy controls
Number of subjects: 36
Study 39568009 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Kasai operation combined with autologous bone marrow mononuclear cell (BMMNC) infusion
Number of subjects: 20
Study 39568009 — intervention group
Group type: COMPARATOR
Intervention: Modified Kasai operation
Number of subjects: 20
Study 39568042 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal carriage of carbapenem-resistant gram-negative bacteria (CR-GNB)
Number of subjects: 150
Study 39568042 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation of CR-GNB from stool
Number of subjects: 150
Study 39568547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga, practiced 3 times a week for 8 weeks
Number of subjects: 98
Study 39568547 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 98
Study 39568632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hockey Fans in Training (Hockey FIT) intervention
Number of subjects: 997
Study 39568632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 997
Study 39568632 — intervention group
Group type: COMPARATOR
Intervention: Difference between intervention and control
Number of subjects: 997
Study 39568632 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-study related serious adverse events
Number of subjects: 997
Study 39568724 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g sunflower lecithin (LPL)
Number of subjects: 18
Study 39568724 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g oat polar lipids (OPL)
Number of subjects: 18
Study 39568724 — intervention group
Group type: COMPARATOR
Intervention: 18 g rapeseed oil (RSO)
Number of subjects: 18
Study 39568724 — intervention group
Group type: COMPARATOR
Intervention: Reference white wheat bread (WWB)
Number of subjects: 18
Study 39568790 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% 5-Fluorouracil (5FU) cream
Number of subjects: 12
Study 39569196 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP) with emtricitabine-tenofovir (FTC-TDF) or emtricitabine-tenofovir alafenamide (FTC-TAF)
Number of subjects: 144
Study 39569196 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 144
Study 39569316 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care from cardiologists, nephrologists, endocrinologists, and specialist nurses at an integrated clinic
Number of subjects: 131
Study 39569316 — intervention group
Group type: COMPARATOR
Intervention: Traditional care from separate specialists
Number of subjects: 131
Study 39569437 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine with guanidinoacetic acid
Number of subjects: 0
Study 39569437 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39569450 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient renourishment (25.10 ± 19.73 days)
Number of subjects: 103
Study 39569450 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool energy content at discharge (AN-DIS: 5.72 ± 0.86 kcal/g)
Number of subjects: 103
Study 39569450 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and BMI at admission and discharge
Number of subjects: 103
Study 39569450 — intervention group
Group type: COMPARATOR
Intervention: Non-eating disorder controls (non-ED)
Number of subjects: 103
Study 39569496 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-proven incident ischemia (defined as recurrent ischemic stroke or at least 1 incident lacune or incidental diffusion-weighted imaging-positive lesion on brain MRI at 6 months)
Number of subjects: 249
Study 39569496 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-proven incident ischemia
Number of subjects: 249
Study 39569505 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable leadless pacemakers
Number of subjects: 117
Study 39569505 — intervention group
Group type: COMPARATOR
Intervention: Nonremovable leadless pacemakers
Number of subjects: 117
Study 39569505 — intervention group
Group type: COMPARATOR
Intervention: Conventional transvenous pacemakers
Number of subjects: 117
Study 39569542 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-administered audio recordings
Number of subjects: 50
Study 39569553 — intervention group
Group type: EXPERIMENTAL
Intervention: Govorestat (AT-007)
Number of subjects: 47
Study 39569553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 39569560 — intervention group
Group type: EXPERIMENTAL
Intervention: More MVPA (Moderate to Vigorous Physical Activity) relative to LPA (Light Physical Activity) and sedentary time
Number of subjects: 107
Study 39569560 — intervention group
Group type: EXPERIMENTAL
Intervention: More LPA relative to MVPA and sedentary time
Number of subjects: 107
Study 39569560 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing sedentary time or engaging in MVPA at the expense of LPA during childcare
Number of subjects: 107
Study 39569704 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-implemented imitation measures delivered with support from a remote virtual assessor
Number of subjects: 177
Study 39569704 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-implemented intervention delivered through the Part C early intervention (EI) system
Number of subjects: 177
Study 39569806 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (asymmetric biphasic rectangular waveforms) applied to the common fibular nerve compartment of the sciatic nerve.
Number of subjects: 38
Study 39569806 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation (asymmetric biphasic rectangular waveforms) applied to the tibial nerve compartment of the sciatic nerve.
Number of subjects: 38
Study 39569806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (common fibular and tibial nerve compartments)
Number of subjects: 38
Study 39570031 — intervention group
Group type: EXPERIMENTAL
Intervention: S315 (480 mg, 960 mg, 1920 mg, 3840 mg, 7680 mg)
Number of subjects: 41
Study 39570031 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 41
Study 39570031 — intervention group
Group type: EXPERIMENTAL
Intervention: S315 (various doses)
Number of subjects: 41
Study 39570031 — intervention group
Group type: EXPERIMENTAL
Intervention: S315
Number of subjects: 41
Study 39570078 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant
Number of subjects: 501
Study 39570078 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet
Number of subjects: 501
Study 39570078 — intervention group
Group type: COMPARATOR
Intervention: Control (no competing LAA mechanisms)
Number of subjects: 501
Study 39570213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 168
Study 39570234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796
Study 39570234 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study 39570238 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation Symptoms Questionnaire (AFSQ)
Number of subjects: 267
Study 39570238 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiography documented AF
Number of subjects: 267
Study 39570242 — intervention group
Group type: EXPERIMENTAL
Intervention: Amulet occluder
Number of subjects: 1878
Study 39570242 — intervention group
Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 1878
Study 39570246 — intervention group
Group type: EXPERIMENTAL
Intervention: TriClip
Number of subjects: 69
Study 39570246 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study 39570303 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients (Edmonton Frail Scale REFS values ≥8)
Number of subjects: 194
Study 39570303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic patients
Number of subjects: 194
Study 39570303 — intervention group
Group type: EXPERIMENTAL
Intervention: Myosteatotic patients
Number of subjects: 194
Study 39570303 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 194
Study 39570398 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled probes targeting prostate-specific membrane antigen (PSMA)
Number of subjects: 12
Study 39570398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid PET/MRI system
Number of subjects: 12
Study 39570545 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 5089
Study 39570583 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (group 2)
Number of subjects: 530
Study 39570583 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/FOLFIRI plus bevacizumab (group 1)
Number of subjects: 530
Study 39570583 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX/FOLFIRI plus panitumumab (group 4)
Number of subjects: 530
Study 39570583 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/FOLFIRI plus bevacizumab (group 3)
Number of subjects: 530
Study 39570583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 530
Study 39570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 100
Study 39570589 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (Control)
Number of subjects: 100
Study 39570588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing intervention (provision of hearing aids and related technologies, counseling, education)
Number of subjects: 977
Study 39570588 — intervention group
Group type: COMPARATOR
Intervention: Health education control (individual sessions covering topics relevant to chronic disease, disability prevention)
Number of subjects: 977
Study 39570590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency follow-up testing (CT scans and CEA screening at 6, 12, 18, 24, and 36 months after surgery); 1227 patients.
Number of subjects: 2509
Study 39570590 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency follow-up testing (CT scans and CEA screening at 12 and 36 months after surgery); 1229 patients.
Number of subjects: 2509
Study 39570620 — intervention group
Group type: EXPERIMENTAL
Intervention: Olverembatinib 30 mg every other day
Number of subjects: 80
Study 39570620 — intervention group
Group type: EXPERIMENTAL
Intervention: Olverembatinib 40 mg every other day
Number of subjects: 80
Study 39570620 — intervention group
Group type: EXPERIMENTAL
Intervention: Olverembatinib 50 mg every other day
Number of subjects: 80
Study 39570620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior ponatinib treatment
Number of subjects: 80
Study 39570620 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior asciminib resistance
Number of subjects: 80
Study 39570681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 153
Study 39570681 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 153
Study 39570688 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths use
Number of subjects: 120
Study 39570688 — intervention group
Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 120
Study 39570688 — intervention group
Group type: COMPARATOR
Intervention: Stress
Number of subjects: 120
Study 39570688 — intervention group
Group type: COMPARATOR
Intervention: Depression
Number of subjects: 120
Study 39570708 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate treatment
Number of subjects: 0
Study 39570708 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin])
Number of subjects: 0
Study 39570708 — intervention group
Group type: COMPARATOR
Intervention: Targeted therapy (everolimus [Afinitor] and sunitinib [Sutent])
Number of subjects: 0
Study 39570708 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 39570749 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag starting doses of 100, 150, and 200 μg twice daily for body weight groups ≥9 to <25 kg, ≥25 to <50 kg, and ≥50 kg respectively; maximum allowed doses of 800, 1200, and 1600 μg twice daily.
Number of subjects: 63
Study 39570749 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag dose regimen for pediatric PAH patients.
Number of subjects: 63
Study 39570957 — intervention group
Group type: EXPERIMENTAL
Intervention: ADaptivE PrenaTal (ADEPT) intervention
Number of subjects: 0
Study 39570957 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 39570957 — intervention group
Group type: EXPERIMENTAL
Intervention: NMM study (adaptive components of the intervention)
Number of subjects: 0
Study 39570992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (oCEE) - Premarin, 0.45 mg/d
Number of subjects: 299
Study 39570992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (tE2) - Climara, 50 μg/d
Number of subjects: 299
Study 39570992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 39571113 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated heart-health assessment (AH-HA) tool
Number of subjects: 645
Study 39571113 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 645
Study 39571155 — intervention group
Group type: EXPERIMENTAL
Intervention: PANDAH app
Number of subjects: 100
Study 39571155 — intervention group
Group type: EXPERIMENTAL
Intervention: PANDAH app for 6 months
Number of subjects: 100
Study 39571155 — intervention group
Group type: COMPARATOR
Intervention: Care as usual or waiting list
Number of subjects: 100
Study 39571150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Lifestyle Intervention (MHB)
Number of subjects: 50
Study 39571150 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 50
Study 39571171 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 30
Study 39571171 — intervention group
Group type: COMPARATOR
Intervention: CAR-T
Number of subjects: 30